CollPlant Biotechnologies Ltd
All Connections
7 total
All Connections
7 totalGeorge Walter Loewenbaum is part of the Loewenbaum Group which filed SC 13D/A for 12.2% stake in CollPlant on 2025-11-07; Loewenbaum simultaneously became non-voting board observer on 2025-12-31
Ami Sagy has held 10%+ of CollPlant since at least February 2019 per SC 13D filing history; maintained position through at least November 2025 per SC 13D/A
H.C. Wainwright acted as exclusive placement agent for both the June 2025 and February 2026 registered direct offerings of CollPlant shares; received 7% placement fee on both (~$252K in 2025, ~$140K in 2026)
AbbVie (Allergan) is CollPlant's primary commercial partner under a 2021 development and global commercialization agreement for dermal/soft tissue fillers; paid $10M milestone in June 2023 and $2M milestone in February 2025
Yissum Research Development Company of the Hebrew University of Jerusalem holds IP license rights related to rhCollagen technology licensed to CollPlant under 2004 agreement; former Executive Chief Scientist Prof. Oded Shoseyov had personal interest in this agreement
Greenberg Traurig P.A. (Tel Aviv) serves as US federal securities law counsel for both CollPlant Biotechnologies and ParaZero Technologies, as confirmed in their respective 424B5 Legal Matters sections (Feb and Mar 2026).
Thompson Hine LLP appeared as placement agent's counsel in CollPlant 2021 offerings (2 EFTS hits, accessions 0001493152-21-024079 and 0001493152-21-011556). Connection is historical (2021) rather than current (2026 offering uses different structure).
All Findings
9 total
All Findings
9 totalfinancial (5)
AbbVie (Allergan) paid CollPlant a $2M milestone payment in February 2025 under the 2021 Development Agreement for dermal filler products; a prior $10M milestone was received June 2023
From 20-F liquidity section: '$2 million payment from AbbVie to us' on milestone achievement in February 2025. Prior milestone: $10M in June 2023. Company states 'there can be no assurance that we will receive any further payments under the AbbVie Development Agreement.'
CollPlant completed registered direct offering of 1,200,002 shares at $3.00, raising $3.6M gross via HC Wainwright; concurrent private placement of 1,200,002 warrants at $3.00, 3.5-year expiry
424B5 filed 2025-06-02, Registration 333-269087 (F-3 from Dec 2022). Offering at ~$3.00 vs closing price of $4.54 on May 29, 2025 — a 34% discount. Non-affiliate market cap at offering: ~$34.9M.
CollPlant filed new F-3 shelf registration (333-292640) on January 9, 2026; it became effective January 16, 2026 — only 7 days after filing; used for February 2026 offering 21 days later
F-3 filed 2026-01-09, EFFECT filed 2026-01-16. 424B5 offering on 2026-02-06. The rapid 7-day effectiveness suggests automatic or expedited shelf effectiveness (typical for FPIs on Form F-3). The accelerated execution indicates urgency around the February offering.
CollPlant completed registered direct offering of 1,600,000 shares at $1.25 (58% below June 2025 offering price), raising $2.0M gross via HC Wainwright; concurrent private placement of 3,200,000 warrants at $1.25 (Series A 5-yr + Series B 18-mo) plus 96,000 PA warrants
424B5 filed 2026-02-06, Registration 333-292640. F-3 filed 2026-01-09, effective 2026-01-16. This is the company's second registered direct offering in 9 months. Offering price of $1.25 represents a 22% discount to the Feb 4, 2026 closing price of $1.61. Non-affiliate market cap at offering: ~$18.2M.
CollPlant FY2025 20-F discloses going concern doubt: $5.6M cash, $9.4M operating cash burn, net loss $11.5M, accumulated deficit $124.8M; auditors issued going concern qualification
20-F filed 2026-03-26 states: 'Based on the Company's cash position as of March 15, 2026, alongside projected continued negative cash flows, the Company's resources are not sufficient to fund its operation for the next 12 months.' Management initiated Q4 2025 cost cutting and significant workforce reduction.
corporate (4)
Ami Sagy holds 11.4% of CollPlant (1,637,086 shares) per SC 13D/A filed November 28, 2025; Sagy's position dates to at least February 2019 (original SC 13D)
Ami Sagy has been a 10%+ holder since at least 2019. Filed original SC 13D in February 2019 and at least 4 amendments through November 2025. No further detail on identity (individual vs entity) available from current search.
Loewenbaum Group (George Walter Loewenbaum, Lillian S. Loewenbaum, Elizabeth S. Loewenbaum, Loewenbaum Residence Trust) holds 12.2% of CollPlant (1,760,531 shares); George Loewenbaum simultaneously became non-voting board observer on December 31, 2025
Ownership based on SC 13D/A filed November 7, 2025. Board observer seat commenced December 31, 2025. Coordinated entry: large block position + governance access obtained within ~2 months.
Yehiel Tal (CEO since 2010) became Interim Chairman of the Board in December 2025, replacing a prior chairman; company operating with CEO-as-chair structure under going concern conditions
20-F states Tal has served as interim chairman since December 2025. This represents a consolidation of executive and board authority. Prior chairman not identified in this search.
Anomalous cluster of 10 Form 3 initial ownership filings for CollPlant on 2026-03-18/19, including by executives who have held their roles since 2011–2018; possible compliance deficiency or corporate restructuring trigger
Form 3 is an initial statement of beneficial ownership filed when a person first becomes a reporting person. Ten current officers/directors filed Form 3s on March 18-19, 2026, including Eran Rotem (CFO since 2012), Philippe Bensimon (VP since 2011), Abraham Havron (Director since 2016), and Elan Penn (Director since 2018). Filing initial Form 3s years after assuming reporting-person roles may indicate a prior compliance gap or a technical corporate event that required new initial filings.